The roles played by the N-linked glycans of the Friend murine leukemia virus envelope proteins were investigated by site-specific mutagenesis. The surface protein gp7O has eight potential attachment sites for N-linked glycan; each signal asparagine was converted to aspartate, and mutant viruses were tested for the ability to grow in NIH 3T3 fibroblasts. Seven of the mutations did not affect virus infectivity, whereas mutation of the fourth glycosylation signal from the amino terminus (gs4) resulted in a noninfectious phenotype. Characterization of mutant gene products by radioimmunoprecipitation confirmed that glycosylation occurs at all eight consensus signals in gp7O and that gs2 carries an endoglycosidase H-sensitive glycan. Elimination of gs2 did not cause retention of an endoglycosidase H-sensitive glycan at a different site, demonstrating that this structure does not play an essential role in envelope protein function. The gs3-mutation affected a second posttranslational modification of unknown type, which was manifested as production of gp7O that remained smaller than wild-type gp7O after removal of all N-linked glycans by peptide N-glycosidase F. The gs4-mutation decreased processing of gPr8O to gPr9O, completely inhibited proteolytic processing of gPr9O to gp7O and Prl5(E), and prevented incorporation of envelope products into virus particles. Brefeldin A-induced mixing of the endoplasmic reticulum and parts of the Golgi apparatus allowed proteolytic processing of wild-type gPr9O to occur in the absence of protein transport, but it did not overcome the cleavage defect of the gs4-precursor, indicating that gs4-gPr9O is resistant to the processing protease. The work reported here demonstrates that the gs4 region is important for env precursor processing and suggests that gs4 may be a critical target in the disruption of murine leukemia virus env product processing by inhibitors of N-linked glycosylation.
Retroviral envelope genes (envs) encode glycosylated precursor proteins that are converted by oligosaccharide processing and proteolytic cleavage into two mature viral membrane subunits, the surface protein (SU) and the transmembrane protein (TM). These proteins mediate binding of virions to host cell surface receptors and penetration of viral cores into the host cell cytoplasm. In addition to their roles in viral replication, retroviral env proteins are important determinants of viral pathogenicity (e.g., see references 34, 55, and 65). The overall structure and processing pathway of murine leukemia virus (MuLV) env products have been characterized (reviewed in reference 36). The first identifiable product, gPr8O, carries endoglycosidase H (endo H)-sensitive high-mannose glycans. On the next discrete intermediate, gPr9O, most of the N-linked glycans have become endo H resistant, and 0-linked glycans are present. gPr9O is rapidly cleaved at a dibasic amino acid cleavage site into gp7O (SU) and Prl5(E) (TM), which remain associated via disulfide linkages. After incorporation into virus particles, Prl5(E) is further processed into p15(E) by removal of a small C-terminal peptide.
The work presented here examines the function of the N-linked glycans of the env products of Friend MuLV. Inhibitors of N-linked glycosylation (42, 48) or early processing of N-linked oligosaccharides (40) block proteolytic processing and transport of MuLV envelope proteins and production of infectious virus. This suggests that addition and some processing of N-linked glycan is required for "The glycosylation signals of Friend MuLV are numbered sequentially from the N terminus of gp7O.
b The amino acid sequence surrounding each signal is shown, with the mutant Asp residue capitalized. The mutagenic nucleotide sequence is shown as the complement of the oligonucleotide actually used, with non-wild-type bases capitalized. For those mutations for which a new restriction site was introduced to monitor the presence of the mutation, the recognition sequence is shown in italics and the enzyme is indicated below the site.
regions surrounding each mutagenic oligonucleotide were confirmed by DNA sequencing, and mutant envs were placed into complete viral genomes for analysis. Some of the mutant envs were cloned into viral vectors containing EcoRI-permuted genomes of Friend MuLV (50) . A vector containing a nonpermuted Friend virus genome with two long terminal repeats, pLRB132, was used for the remainder of the mutants. pLRB132, constructed in this laboratory from p57/19A (50) , contains a small amount of env duplicated 5' to the complete genome and gag and some pol sequences 3' to it. To ensure that the phenotypes of the noninfectious gs4-mutant and the unexpected mobility alteration of gs3-gp70 were due to the Asn-)Asp mutations, the complete sequence of a small restriction fragment containing each mutation was determined, and mutant viral genomes that contained only these sequenced fragments from the mutagenized plasmids were constructed. These constructs displayed the same phenotypes as the original gs3-and gs4-viruses. Sequences were determined by the dideoxy method on single-stranded and double-stranded templates by using Sequenase (U.S. Biochemicals).
Viral culture and immunological and biochemical procedures. Viral culture (40) , indirect immunofluorescence (30) , and radiolabelling and radioimmunoprecipitation (39) mutants were labelled for 1 h with [35S]cysteine, and cell lysates were immunoprecipitated with hyperimmune antigp7O serum. Cell lines for the infectious mutants were derived from transfections like those described above; the cell line for the noninfectious gs4-mutant was generated with pseudotyped virus stocks prepared in retroviral vector packaging cell lines. All eight glycosylation signal mutants produced gPr8O that was slightly smaller than that of the wild type ( Fig. 2A ). This size shift is due to the loss of N-linked glycan from each mutant product, since each of the mutant gPr8Os comigrated with wild-type gPr8O after removal of all N-linked glycans with PNGase F (Fig. 2B ). These data demonstrate that all eight glycosylation signal sequences in wild-type Friend MuLV gp7O are utilized, confirming previous reports based on protein sequencing (5, 12) .
Characterization of mutant gp7Os. Mature gp70s were found in infected cells for the seven infectious mutants but not in cells infected with the defective gs4-mutant ( Fig.  2A) . The mutant gp70s were all smaller than wild-type gp7O, consistent with the absence of an N-linked glycan. Cells expressing the gs5-mutant reproducibly contained a lower ratio of gp7O to gPr8O, and gs5-virions contained less env protein than wild-type particles (data not shown), but this did not have a significant effect on viral growth. After deglycosylation with PNGase F, six of the seven mutant gp7os comigrated with wild-type gp7O, as expected (Fig. 2B) . Surprisingly, the gs3 gp7O was smaller than the wild-type gp7O even after removal of all N-linked glycans. This observation, together with the fact that the deglycosylated gs3-gPr8O was the same size as the wild-type gPr80, implies that the gs3 mutation has a second effect on a posttranslational modification that occurs after addition of N-linked glycans and does not directly involve these moieties.
Virion-associated gp7Os made by the infectious mutants were also smaller than the wild-type product (Fig. 3) Fig. 3 , but they were clearly distinguished in other experiments (data not shown). The gp7Os from the gs5-, gs6-, gs7-, and gs8-mutants were smaller than that from the wild type, while the three N-terminal tryptic fragments from these mutants comigrated with those from the wild type, consistent with the location of these glycosylation signals in the C-terminal domain of gp7O.
For the gs3 mutant, gp7O and its 51-kDa fragment were smaller than those from the wild type, whereas its 36-and 34-kDa fragments comigrated with the corresponding wildtype fragments. In this case, the shift in the size of the 51-kDa fragment was not due to the loss of the glycan at gs3, since removal of N-linked glycans with PNGase F failed to eliminate the size difference (data not shown), and as shown below, the 51-kDa fragment contains only gsl and gs2. The mobility shift of the gs3-51-kDa fragment therefore resulted from the second processing alteration associated with the gs3-mutation, as noted above (Fig. 2B) . These data map this modification to the region of gp7O between gs2 and gs3, since gs2 is present on the 36-kDa fragment that does not carry this modification and the 51-kDa fragment that carries this modification terminates before gs3. This is a region in which 0-linked carbohydrate is attached to gp7O (reference 39 and unpublished data). Although gs3-gp7O does carry 0-linked carbohydrate (data not shown), it is possible that gs3-gp7O carries less 0-linked carbohydrate than wild-type gp7O. Alternatively, there may be a different posttranslational modification in this region of gp7O that is affected by the gs3-mutation.
An endo H-sensitive glycan is attached at gs2. Endo H removes high-mannose and some hybrid N-linked glycans but not complex forms (59 (Fig. 4) . Endo H digestion of the fragment from gslvirus converted it into a product that comigrated with the untreated fragment from the gsl-gs2-double mutant; however, endo H had no effect on the mobility of the fragment from gs2- only a small amount of 70-kDa protein was associated with gs4-virions. This material is not gp7O, since it was not immunoprecipitated by the hyperimmune anti-gp7O serum (Fig. 5B ) even though this serum did precipitate gs4-gPr8O (Fig. SA) .
The kinetics of processing of gs4-env products was investigated with a 1-h pulse label followed by chase periods of various times (Fig. 6) Thus, the gs4-mutation has two effects on env processing: a decrease in maturation of gPr8O to gPr9O and a stringent blockage of gPr90 proteolytic processing.
The lack of proteolytic processing of gs4-gPr9O might be due either to its failure to be translocated into the subcellular compartment where proteolysis occurs or to an inherent resistance of the mutant precursor to the protease involved. These possibilities were tested by using the drug brefeldin A (BFA) to bypass the requirement for translocation. BFA inhibits transport of proteins from the endoplasmic reticulum into the Golgi apparatus (26) and induces collapse of Golgi apparatus membrane structures and enzymes into the endoplasmic reticulum (4, 20) . In the presence of BFA, MuLV env products were not incorporated into virions or secreted from cells (data not shown). Wild-type env precursor was slowly cleaved into SU and TM domains, with approximately 50% of the labelled env protein found as cleavage product by 8 h after the beginning of the chase period (Fig.  7) . This result indicates that at least a fraction of the processing protease is present and active in the combined endoplasmic reticulum-Golgi apparatus compartment in BFA-treated cells. Thus, treatment with BFA bypasses whatever translocation steps are normally required for env precursors to be available to the processing protease. In contrast to what is seen for wild-type env products, no processing of gs4-precursor into SU and TM domains was detected within 8 h of the start of the chase. Since translocation is not required for proteolytic processing of envelope precursor in the presence of BFA, these data argue that the processing protease does not recognize the mutant protein.
To determine whether the partial block in gs4-gPr8O processing to gPr9O and/or the failure of gs4-gPr9O to be processed to gp7O 
DISCUSSION
The functions of the N-linked glycans carried on MuLV env proteins have previously been studied by using drugs that block the addition of these structures to proteins or that inhibit processing of high-mannose forms. Tunicamycin, which blocks transfer of N-linked glycans to nascent polypeptides, inhibits the processing of MuLV env precursors into gp7O and Prl5(E) and the incorporation of envelope proteins into virus particles (40, 42, 48) . A study using monoclonal antibodies against a conformational epitope on gp7O suggested that tunicamycin interferes with proper folding of the env precursor (35). 1-Deoxynojirimycin, which inhibits the glycosidases that remove the three glucose residues present on the initially transferred glycans, also interferes with transport and proteolytic processing of the env precursor (40) . This observation indicates that at least some of the N-linked glycans need to undergo processing for proper function of the env protein. Taken together, these data suggest that N-linked glycans function at multiple steps in env precursor folding and processing.
The characterization of glycosylation signal mutations of Friend MuLV env proteins reported here provides a more precise picture of the role of N-linked glycans in envelope protein function. Only one glycosylation mutation in env had sufficient impact on protein function to interfere with viral growth. Such attachment site specificity for the effect of glycosylation mutations has been observed for a number other proteins (e.g., as described in references 9, 23, 28, and 64). The Asn-302--*Asp mutation at gs4 interferes with the maturation of gPr8O to gPr9O and causes accumulation of gPr90 because of a stringent block in its conversion to gp7O and Prl5(E). It is possible that the gs4 glycan is a critical target for one or more of the inhibitors that block attachment and processing of N-linked glycans. gPr8O has been localized to the endoplasmic reticulum by its characteristic endo H-sensitive glycans (36) . The reduced processing of gs4-gPr8O to gPr9O may be due to an increased percentage of improperly folded or oligomerized subunits that are not competent for translocation into the Golgi apparatus, as has been observed for a number of other glycosylation mutant proteins (8, 11, 28) . The gs4-cleavage defect was not suppressed by BFA, which bypasses the protein transport normally required for proteolytic processing of wild-type gPr90. In addition, the N-linked and 0-linked glycans found on gs4-gPr9O are normal in their sensitivity to endoglycosidases, consistent with it being located in the proper subcellular compartment. It thus appears that gs4-gPr9O is probably transported into the Golgi compartment in which proteolytic cleavage normally occurs, and it is resistant to the processing protease.
Functional roles of specific N-linked glycosylation signals have previously been reported for the SU proteins of human immunodeficiency virus type 1 (HIV-1) (gpl20) and HIV-2 (gplO5). Unlike the results reported here for the gs4-mutation of gp7O, no effects on protein maturation were found. In HIV-1, elimination of one of the four glycosylation signals of gpl20 examined by site-directed mutagenesis interferes with viral growth because of a defect in a postbinding step in the infection cycle (64) . In HIV-2, elimination of one of the three glycosylation signals near or within the region believed to comprise the CD4-binding site of gplO5 markedly decreased its affinity for CD4 (27) .
Glycosylation signals homologous to those of Friend MuLV env are largely conserved among MuLV and feline leukemia virus (FeLV) envs ( Table 2 ), suggesting that there has been selective pressure for their retention. It was therefore somewhat surprising that viral growth in cell culture is insensitive to the individual elimination of seven of the eight glycosylation signals in the SU domain of Friend MuLV. The presence of an endo H-sensitive glycan in the N-terminal domain of ecotropic and polytropic MuLV gp70s (37, 38) also argues for selective pressure on this structural feature, particularly since it is not attached at precisely the same site in the two classes of envs. This glycan was found to be attached at gs2 of Friend MuLV, which is conserved among ecotropic envs but is not found in polytropic envs ( Table 2 ). The glycosylation signal in this domain that is conserved among polytropic envs but is not found in ecotropic envs may be the attachment site of the N-terminal endo H-sensitive glycan carried by polytropic SU proteins. There are several plausible ways to reconcile the expectation of selective pressure on many of these glycosylation signals with the observation that seven out of eight are dispensable for growth in NIH 3T3 fibroblasts. First, N-linked glycans may possess functions that are relevant in host animals but not in cell culture, such as masking of epitopes (51, 66) or protecting against proteolytic degradation. Second, small effects on growth rate that were not detected in cell culture may be important in animals, where selection for faster-growing variants should occur. Third, the mutations may have larger effects on growth in other cell types that are important targets in mice. The glycosylation signal that did prove to be sensitive to mutation, gs4, is one of two that are fully conserved among the closely related MuLV and FeLV genes. Examination of known sequences of retroviral envs shows that a homolog of gs4 is retained even in genes with very little sequence similarity in SU domains. The gs4 motif consists of a hydrophobic glycosylation signal (usually) seven amino acids N terminal to an invariant Cys-Trp-Leu-Cys sequence (Table 3) . Biochemical data have demonstrated that, for the Friend MuLV env product, one or both of these cysteines are involved in disulfide bonding between gp70 and p15(E) (unpublished data). The evolutionary association of gs4 with these cysteine residues suggests that this glycan plays a role in establishing correct interdomain disulfide bonding in gPr8O. Data from a number of systems suggest that N-linked glycans affect protein tertiary structure by controlling the pattern of disulfide bonds formed during folding and oligomerization (28, 52, 56, 60, 66) , and two observations indicate that the gs4-mutation affects overall env precursor structure, in particular in or near the p15(E) domain. First, the gs4-mutation exerts an effect at a distance on the gp7O-Prl5(E) cleavage site (amino acid 302 versus 445), suggesting a change in tertiary structure. Second, anti-p15(E) monoclonal antibody 9E8 recognizes gs4-gPr8O much more efficiently than wild-type gPr8O, demonstrating that the structure or accessibility of p15(E) sequences within gPr8O is affected by the gs4-mutation. If the Friend MuLV gs4 glycan is involved in regulation of interdomain disulfide bonding, the evolutionary retention of a homologous site implies that this structural motif may be used in a surprisingly diverse group of retroviral envs. It will be interesting to determine whether mutations in the gs4 homologs of these other envs yield similar phenotypes.
The data presented above do not distinguish between effects due to the absence of an N-linked glycan at position 302 and those due to the presence of an aspartic acid residue at this position. Caution is needed in interpreting phenotypes of glycosylation mutations as due to the loss of the glycan per se. For example, the phenotypes of glycosylation mutations in HLA-2A depend on the specific amino acid substitution introduced (46), suggesting a major role for the amino acid sequence at the glycosylation site. This is also suggested by the analysis of the glycosylation site in HIV-1 gpl20 discussed above, where mutations adjacent to or within the glycosylation signal that would not be expected to affect glycan addition had phenotypes similar to those of mutations that destroy the glycosylation signal (64) . In addition, the phenotypes of glycosylation mutations in HIV-1 gpl20 (64) and vesicular stomatitis virus G protein restore the glycosylation signal, suggesting that the presence of N-linked glycans at these sites is not stringently required for protein function. Examination of other mutations in and near gs4 of gp7O and isolation and characterization of revertants of gs4-mutants are under way to determine the relative contributions of the absence of the glycan and the presence of specific amino acids to the phenotypes of gs4 mutations.
This work has shown that all but one of the N-linked glycans of Friend MuLV gp7O are not essential for viral growth, although mutation of at least one of these nonessential sites (gs5) does have a significant effect on protein maturation. Examination of mutants carrying multiple glycosylation mutations is under way to determine the structure(s) of the minimally glycosylated env product(s) that have sufficient protein function for normal viral growth and to investigate ways in which combinations of N-linked glycans contribute to protein function.
